NCT02520011 2023-11-15
Alvocidib Biomarker-driven Phase 2 AML Study
Sumitomo Pharma America, Inc.
Phase 2 Terminated
Clinical Trials
22 trialsNCT03969420 2023-11-09
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT00005074 2020-04-09
Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00005971 2020-04-09
Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00005974 2020-04-08
Flavopiridol in Treating Patients With Recurrent, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT00795002 2018-08-07
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01349972 2017-07-31
Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00957905 2017-03-10
Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00407966 2015-08-04
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00634244 2015-07-07
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00331682 2014-05-28
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00991952 2014-05-26
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00083122 2014-05-21
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006245 2013-06-24
Flavopiridol and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer That Has Not Responded to Previous Paclitaxel
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016939 2013-06-24
Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00023894 2013-06-24
Flavopiridol in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00087282 2013-06-24
Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00020189 2013-06-19
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00464633 2013-02-12
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
Sanofi
Phase 2 Completed
NCT00003256 2013-02-11
Flavopiridol in Treating Patients With Recurrent Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003039 2013-02-05
Flavopiridol in Treating Patients With Recurrent Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003620 2013-01-17
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed